N itrous oxide (N 2 O) was first isolated by Joseph Priestly in 1772 and was recognized as having analgesic properties by Humphrey Davy in 1799, based in part on his self-treatment of a toothache. 1 Davy prophetically noted that because the agent "appears capable of destroying physical pain, it may probably be used with advantage during surgical operations." 2, 3 However, early and mid-19th century human use of N 2 O was more often as a recreational drug at the then common "laughing gas" parties and public demonstrations in theaters, music halls, and carnivals. 4 Despite Horace Wells' unsuccessful initial public administration of N 2 O in 1845 at Massachusetts General Hospital, beginning in the 1860s, Gardner Quincy Colton and his colleagues subsequently mastered and promoted its widespread clinical use in America and Europe. 5 In the intervening 150 years, N 2 O has remained a widely used inhaled anesthetic agent, which has been ostensibly administered safely to several billion surgical patients worldwide. 6, 7 However, the use of N 2 O has not been without problems and controversy. The metabolic effects of N 2 O are centered on the inactivation of cobalamin (vitamin B 12 ) as a coenzyme of methionine synthase. 8 This inhibition of methionine synthase by N 2 O increases plasma homocysteine. 9 Patient and occupational exposures to N 2 O have been associated with a variety of adverse effects, including endothelial dysfunction, 8, 9 leading some to question the continued clinical viability of N 2 O. 10, 11 To date, the Evaluation of Nitrous Oxide in the Gas Mixture for Anesthesia (ENIGMA) trial group has reported perhaps the most troubling clinical findings. 12, 13 In the ENIGMA-I trial, a cohort of 2050 patients having major surgery, across 19 participating centers between April 2003 and June 2004, were randomized to receive N 2 O-free (80% oxygen, 20% nitrogen) or N 2 O-based (70% N 2 O, 30% oxygen) anesthesia. 12 The initial primary ENIGMA outcome was duration of hospital stay, with secondary outcomes being the duration of intensive care, the occurrence of postoperative pneumonia, pneumothorax, pulmonary embolism, wound infection, myocardial infarction, venous thromboembolism, or stroke, and death within 30 days of surgery. No significant difference in duration of hospital stay was observed between the 2 study groups. Compared with patients in the N 2 O-based group, patients in the N 2 Ofree group were less likely to have at least 1 pulmonary complication (7.8% vs 13.0%; adjusted odds ratio of 0.54, 95% confidence interval [CI], 0.40-0.74; P < 0.001) and less likely to have at least 1 major complication (16% vs 21%; adjusted odds ratio of 0.71, 95% CI, 0.56-0.89; P = 0.003). 12 The N 2 O-associated number needed to harm (NNH) for a pulmonary complication was 19.2, and the NNH for any major complication was 20.
The ENIGMA trial group subsequently conducted a follow-up (median, 3.5 years) of their initial cohort of 2050 patients to evaluate survival and the risk of myocardial infarction or stroke. 13 Exposure to N 2 O did not significantly increase the risk of death (hazard ratio 0.98, 95% CI, 0.80-1.20; P = 0.82). In patients administered N 2 O, the adjusted odds ratio for myocardial infarction was 1.59 (95% CI, 1.01-2.51; P = 0.04) and for stroke was 1.01 (95% CI, 0.55-1.87; P = 0.97). Of note, based on the observed 4% vs 5% incidence, the N 2 O-associated NNH for a myocardial infarction during follow-up was 100.
Turan et al. 14 report in this month's issue of the journal on their cohort study of 37,609 adults who underwent noncardiac surgery at the Cleveland Clinic between 2005 and 2009. The primary outcomes of their study were all-cause 30-day mortality and a set of major in-hospital complications, including neurologic, cardiac, pulmonary/ respiratory, infectious, urinary and hemorrhagic, wound disruption, and peripheral vascular complications all based solely on inpatient ICD-9 coding for billing. Receiving N 2 O was associated with decreased 30-day mortality (odds ratio of 0.65, 97.5% CI, 0.45-0.94; P = 0.01). Intraoperative administration of N 2 O was associated with decreased pulmonary/ respiratory morbidity (odds ratio of 0.55, 95% CI, 0.41-0.73; P < 0.001). No differences were observed for the other 7 types of complications.
Turan et al. 14 use the ENIGMA-I trial as the backdrop for the interpretation of their own results and, on its face, this is reasonable. However, there are a number of methodological issues that must be considered when attempting to interpret their results as well as to rectify any differences with those of ENIGMA-I. First and foremost, the study by Turan et al. 14 is observational in nature, and as such the decision to administer N 2 O or not was not a random process. Rather, it was based on a complex, and perhaps unquantifiable set of patient, physician, environmental, and perhaps other characteristics, many of which are also associated www.anesthesia-analgesia.org aNEsthEsia & aNalgEsia with postoperative morbidity and mortality. Any observed effect of N 2 O may be biased by the confounding influence of these characteristics. Studies such as ENIGMA-I minimize such bias by using randomization, which fosters equipoise with respect to these characteristics, including, importantly so, those that cannot be quantified. Although randomizedcontrolled trials remain the "gold standard," it has been demonstrated that well-designed observational studies can also reach similar valid conclusions, 15 the devil being in the details of well-designed studies.
Propensity scores have been used to bridge the gap between observational and randomized studies. Each study participant's probability (i.e., propensity) of receiving or not receiving a treatment is calculated as a function of measured covariates, typically using a logistic regression model. These scores are then used, via several potential mechanisms, to minimize the bias associated with the lack of randomization. Turan et al. 14 used propensity scores to match a subset of 10,755 N 2 O patients with 10,755 non-N 2 O patients with the goal of ensuring that the 2 groups were evenly distributed with respect to the demographic and clinical characteristics that were used to compute the propensity score.
The statistical principles underlying propensity scores have been firmly established, and their use has increased dramatically in the clinical literature over the past 2 decades. 16 Compared with multivariable adjustment, they have often been viewed as a superior approach to address the problem of confounding. The reality is that they are not a panacea; rather, they are only superior in situations that favor their use, and there is little evidence that propensity scores produce substantially different results compared with conventional multivariable methods. 17, 18 Although this finding may be due to publication bias, it can surely be attributed to the fact that propensity scores are not going to solve the problem of unmeasured confounders any better than traditional multivariable adjustment, a fact that will likely leave the bridge between observational and randomized studies forever incomplete.
As the use of propensity scores has flourished, a literature has emerged that provides practical and understandable guidance regarding their use as well as their associated pitfalls. [16] [17] [18] [19] [20] An area where the present study by Turan et al. is deficient relates to the propensity score variable selection and modeling process, which is critical for properly evaluating their validity. We can be somewhat reassured in this regard as the authors have demonstrated that, with some exceptions, the N 2 O and non-N 2 O groups are comparable with respect to the potential confounders. However, this was also the case in their larger population, which may have overcome any model misspecification. Another deficiency relates to the recommendation that the results of both multivariable and propensity score-based approaches be presented, results that Turan et al. do not provide. Lack of such results deprives the reader of valuable information necessary for properly interpreting the study's findings. As a result, we do not know whether the observed results are generalizable to the entire study population or just to those who were able to be matched, which was only 43% of the entire cohort. Last, it has been demonstrated in the setting of cardiovascular mortality that propensity scores developed using administrative data (like those of Turan et al.)
do not necessarily balance patient characteristics contained in the actual corresponding clinical data, and that the use of such administrative data may result in an overestimation of the effectiveness of therapy. 21 However, such issues related to the use of propensity scores may not shed much light on the disagreement between the results reported by Turan et al. 14 and those of the ENIGMA-I trial. 12, 13 There is more to be gained by recognizing that the 2 study populations are likely vastly different. Patients in the ENIGMA-I trial were expected to remain hospitalized for 3 days; the median duration of stay was approximately 7 days. However, the study population in the study by Turan et al. included outpatients and minor procedures, a fact noted in the Discussion of the article. The authors do not provide the reader with information regarding the distribution of inpatients versus outpatients nor the average length of stay for their study population. This is not an insignificant omission for a number of reasons. The mortality and morbidity risk is lower in the study cohort of Turan et al. compared with the ENIGMA-I cohort, and in such lower-risk patients, the effects of N 2 O may be different. Also, one of the primary outcomes in the study by Turan et al. is major in-hospital complications. For outpatients, the time-at-risk is truncated compared with that of inpatients. Thus, the authors' use of odds ratios rather than a rate-based measure of association (e.g., hazard ratios) may obscure the effect of N 2 O on the incidence of the study outcomes, particularly if the time-at-risk differs between the treatment groups.
There has been a significant increase in such retrospective analyses of existing, secondary data to assess both immediate and more longitudinal perioperative outcomes. Such perioperative, observational studies have been facilitated by the development of large-scale databases at a single institution (e.g., Cleveland Clinic or Mayo Clinic) or involving multiple centers (e.g., Surgical Care Improvement Project, National Anesthesia Clinical Outcomes Registry, Multicenter Perioperative Outcomes Group, and National Center for Clinical Outcomes Research). Although such large secondary databases are understandably attractive to researchers seeking to answer questions requiring robust patient samples, discipline and diligence are needed to avoid data mining and generating statistically but not clinically significant results. In response to these concerns, the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) initiative has developed and widely promulgated recommendations on what should be included in an accurate and complete report of an observational study (http://www.strobe-statement.org/). 22, 23 The editorial board of Anesthesia & Analgesia refers to the STROBE statement in its current "Guide for Authors." 24 Of note, Turan et al. 14 fulfilled the STROBE checklist of items that should be included in such a report of a cohort study.
A growing body of evidence supports the avoidance of N 2 O in pediatric and adult patients, 10, 11, 25 including from a cost-benefit perspective. 26 However, the multitude of patients who have been exposed to N 2 O without apparent complications would suggest that further studies are needed on its longer-term side effects. The contrary findings presented here by Turan et al. 14 are difficult to rectify with those of ENIGMA-I because of the very discordant study populations, something that propensity scores cannot solve. Turan et al. would have a more valid counterpoint if they had performed a sensitivity analysis limited to a study population similar to ENIGMA-I. Additional, perhaps more definitive insight will be gained by the current ENIGMA-II trial, which is reportedly prospectively enrolling 7000 noncardiac surgery patients, at intermediate or high risk for coronary artery disease, to assess the N 2 O-associated risk of death and major nonfatal events (myocardial infarction, cardiac arrest, pulmonary embolism, and stroke) 30 days postoperatively. 27 E
